FINHUB Insights

Johnson & Johnson Q1 FY26: where the revenue came from and where it went

The whole income statement of Johnson & Johnson for this quarter, as one diagram: what earned the revenue, and what it went on.

Period
Dec 29, 2025 – Mar 29, 2026
Reported
Apr 22, 2026 10-Q accession 0000200406-26-000087

Revenue$24.1B +10% year over year
Gross profit$16.0B 66% margin
Operating profit$6.4B 27% margin
Net profit$5.2B 22% margin
100% free

It's free. All of it.

A free account opens every diagram. We send one link to confirm your address, and that is the whole of it.

Already have an account? Sign in

The numbers

All figures in billions of U.S. dollars, for Q1 FY26 (period ends Mar 29, 2026).
ItemValueShare of revenueYear over year
Revenue 24.1 100% +10%
Innovative medicine 15.4 64% +11%
Med tech 8.6 36% +8%
Cost of revenue−8.134%
Gross profit16.066% margin+0pp
SG&A−6.025%+2pp
Other−3.515%+0pp
Operating profit6.427% margin+0pp
Interest & other costs−0.4
Tax−0.8
Net profit5.2 22% margin−28pp

Figures are rounded to the precision shown, so a column can differ slightly from its own total.

Source of the numbers: structured XBRL data from the filing (10-Q). The diagram is generated automatically and checked against EDGAR before release. How we calculate it → About and methodology.

304 of 418 companies, most recently reported first